Esophageal Cancer Model

Indication / Application

Evaluation of novel anti-tumor therapeutics, validation of localized photodynamic therapy (PDT) and endoscopic ablation systems, investigation of tumor-stromal cross-talk under chronic inflammation (Barrett's esophagus progression to EAC), and evaluation of anti-metastatic therapeutics.

Modeling Method

1. Xenograft Platforms (CDX/PDX):
   • Subcutaneous Model: Inoculation of established human esophageal cancer lines (e.g., EC109, KYSE-150 for ESCC; OE19, OE33 for EAC) or patient-derived tumor fragments into the flank of immunodeficient mice to track gross tumor volume kinetics.
   • Orthotopic Model: Under high-magnification microsurgery, a precise volume of luc-tagged tumor cells or fragmented tissue is micro-injected into the subserosal/muscular layer of the rodent abdominal esophagus to mimic the anatomical and structural niche.
2. Chemical & Surgical Microenvironment Induction (Syngeneic/De Novo):

• • Carcinogen Induction: Chronic administration of asymmetric nitrosamines (e.g., N-nitrosomethylbenzylamine, NMBA) in rats to systematically induce hyperkeratosis, papillomas, and eventual invasive ESCC.
  • Surgical Reflux Model (Levrat's Anastomosis): Esophagoduodenostomy surgical bypass performed in immunocompetent rats to establish mixed gastroduodenal reflux, reliably driving the chronic inflammation cascade (Esophagitis to Barrett’s Esophagus to EAC).

Clinical Relevance

• Microenvironmental & Anatomical Fidelity: Subcutaneous models provide highly reproducible, high-throughput data for initial cytotoxic screenings. For advanced translational pipelines, orthotopic configurations provide the accurate local tissue architecture, mechanical shear stress, and microvascular network needed to evaluate deep tumor invasion, dysphagia-related cachexia, and spontaneous metastasis to mediastinal lymph nodes.
• Pathological Progression Recapitulation: Our induced platforms flawlessly mirror the clinical pathogenesis seen in human populations. Surgical reflux systems mimic the bile-acid mediated DNA damage responsible for westernized EAC, while the NMBA model captures the multi-stage, field-cancerization progression characteristic of endemic ESCC.

Key Evaluation Endpoints

In Vivo / Longitudinal Monitoring

• Bioluminescence Imaging (BLI): Non-invasive, longitudinal tracking of orthotopic tumor burden, local invasion, and metastatic tracking via luciferase-expressing cell lines.
• High-Resolution Micro-Endoscopy: Endoluminal visualization of mucosal changes, luminal narrowing, and structural mass developments inside the upper GI tract.
• Cachexia & Body Mass Indexing: Meticulous monitoring of animal body weight, dietary patterns, and systemic survival curves.

Histopathology & Immunophenotyping 

• Histomorphological Assessment: Standard H&E staining to classify differentiation grade (well, moderately, or poorly differentiated), invasion depth (mucosa, submucosa, or muscularis propria), and clear surgical margins.
• Immunohistochemistry (IHC) & Immunofluorescence (IF):
  • Proliferation & Apoptosis Indices: Ki-67 scoring and TUNEL staining.
  • Squamous vs. Adenocarcinoma Subtyping: Cytokeratin 5/6 (CK5/6), p63, and SOX2 (ESCC markers) versus Cytokeratin 7 (CK7), MUC1, and CDX2 (EAC markers).
  • Angiogenesis Tracking: CD31 or CD105 microvascular density (MVD) indexing.

Molecular & Systemic Biomarkers

• Gene Expression Profiles: RT-qPCR and Western Blot analysis tracking changes in key clinical therapeutic targets (EGFR, HER2, VEGF, and p53 mutations).
• Inflammatory Cascade Quantitation: Serum multiplex assays assessing chronic inflammatory profiles (e.g., IL-1beta, IL-6, TNF-alpha) associated with reflux-induced tumor progression.